Cure My Disease

Don't miss your cure!

 Log in / Sign up

Measles mystery: how a virus both harms and helps immunity

NCT ID NCT07267585

Knowledge-focused Sponsor: Erasmus Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates the 'measles paradox'—how measles can temporarily weaken the immune system while also providing lifelong protection. Researchers will track immune memory cells in 300 adults before and after measles infection. The goal is to understand how measles causes immune amnesia and how long it lasts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could clarify how measles weakens the immune system long-term, potentially guiding better vaccination strategies.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to direct medical advances, and results depend on accurately tracking immune changes over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The participants in this study are 18 years or older and will be recruited in areas with low vaccination coverage. Recruitment will occur through contacting orthodox protestant student associations, GPs with a large orthodox protestant patient base, orthodox protestant newspapers, and first year medical students at the Erasmus MC. The study does not include an intervention.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Cohort A * 18 years or older * No known history of measles or vaccination * Decided to take MMR vaccination before the upcoming measles outbreak Cohort B * 18 years or older * No known history of measles or vaccination (seronegative confirmed) * Contracted measles during the upcoming outbreak Cohort C * 18 years or older * No known history of measles or vaccination (seronegative confirmed) Cohort D * 18 years or older * Experienced measles during the 2013 outbreak Cohort E * 18 years or older * Received second dose of measles vaccines ±10 years ago Exclusion Criteria: A potential participant who meets any of the following criteria will be excluded from the study: * Diagnosed chronic disease * Immune suppression (due to medication or underlying disease) * Additionally for subjects recruited to Cohort A: * pregnant women or women planning to get pregnant in less than one month after the start of the study. This is a precaution; the MMR vaccine is not recommended for pregnant women. * People who have had a severe allergic reaction (e.g., anaphylaxis) after a previous vaccination.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Measles disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

measles

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Measles disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Erasmus MC

    RECRUITING

    Rotterdam, South Holland, 3015GD, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.